Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease

FASEB Journal

Volumn 30, Issue 12, 2016, Pages 4141-4148

  Goetzl, Edward J ^a,b,c   Kapogiannis, Dimitrios ^d   Schwartz, Janice B ^a,b,c   Lobach, Iryna V ^a   Goetzl, Laura ^e   Abner, Erin L ^f   Jicha, Gregory A ^f   Karydas, Anna M ^a   Boxer, Adam ^a   Miller, Bruce L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Jewish Home of San Francisco   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Biomarkers; Cognition; Neurotransmission; Proteinopathy

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; MEMBRANE PROTEIN; NEUROGRANIN; NEUROMODULIN; SERINE; SYNAPSIN I; SYNAPTIC PROTEIN; SYNAPTOPHYSIN; SYNAPTOPODIN; SYNAPTOTAGMIN; SYNAPTOTAGMIN II; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; HUMAN; IMMUNOADSORPTION; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; PRECIPITATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; VERY ELDERLY; BLOOD; METABOLISM; PHYSIOLOGY; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITION; CROSS-SECTIONAL STUDIES; EXOSOMES; FRONTOTEMPORAL DEMENTIA; HUMANS; LONGITUDINAL STUDIES; SYNAPSES; TAU PROTEINS;

EID: 85002335900     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201600816R     Document Type: Article

References (36)

1. Kalia, M. (2008) Brain development: anatomy, connectivity, adaptive plasticity, and toxicity. Metabolism 57, S2-S5
2. Tau, G. Z., and Peterson, B. S. (2010) Normal development of brain circuits. Neuropsychopharmacology 35, 147-168
3. Selkoe, D. J. (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791
4. Clare, R., King, V. G., Wirenfeldt, M., and Vinters, H. V. (2010) Synapse loss in dementias. J. Neurosci. Res. 88, 2083-2090
5. DeKosky, S. T., and Scheff, S.W. (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27, 457-464
6. Masliah, E., Terry, R. D., Alford, M., DeTeresa, R., and Hansen, L. A. (1991) Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am. J. Pathol. 138, 235-246
7. Davidsson, P., and Blennow, K. (1998) Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int. Psychogeriatr. 10, 11-23
8. Reddy, P.H., Mani, G., Park, B. S., Jacques, J., Murdoch, G., Whetsell, W., Jr., Kaye, J., and Manczak, M. (2005) Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimers Dis. 7, 103-117, discussion 173-180
9. Kapogiannis, D., Boxer, A., Schwartz, J. B., Abner, E. L., Biragyn, A., Masharani, U., Frassetto, L., Petersen, R. C., Miller, B. L., and Goetzl, E. J. (2015) Dysfunctionally phosphorylated type 1 insulin receptor substrate inneural-derived blood exosomes of preclinical Alzheimer's disease. FASEB J. 29, 589-596
10. Goetzl, E. J., Boxer, A., Schwartz, J. B., Abner, E. L., Petersen, R. C., Miller, B. L., and Kapogiannis, D. (2015) Alteredlysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology 85, 40-47
11. Goetzl, E. J., Boxer, A., Schwartz, J. B., Abner, E. L., Petersen, R. C., Miller, B. L., Carlson, O.D., Mustapic, M., and Kapogiannis, D. (2015) Low neural exosomal levels of cellular survival factors in Alzheimer's disease. Ann. Clin. Transl. Neurol. 2, 769-773
12. Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., and Goetzl, E. J. (2015) Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement. 11, 600-607.e1
13. Miyakawa, T., Yared, E., Pak, J. H., Huang, F. L., Huang, K. P., and Crawley, J. N. (2001) Neurogranin null mutant mice display performance deficits on spatial learning tasks with anxiety related components. Hippocampus 11, 763-775
14. Glavan, G., Schliebs, R., and Zivin, M. (2009) Synaptotagmins in neurodegeneration. Anat. Rec. (Hoboken) 292, 1849-1862
15. Gordon, S. L., and Cousin, M. A. (2013) X-linked intellectual disability-associated mutations in synaptophysin disrupt synaptobrevin II retrieval. J. Neurosci. 33, 13695-13700
16. Baker, K., Gordon, S. L., Grozeva, D., van Kogelenberg, M., Roberts, N. Y., Pike, M., Blair, E., Hurles, M. E., Chong, W. K., Baldeweg, T., Kurian, M. A., Boyd, S. G., Cousin, M. A., and Raymond, F. L. (2015) Identification of a human synaptotagmin-1 mutation that perturbs synaptic vesicle cycling. J. Clin. Invest. 125, 1670-1678
17. Irizarry, M. C., Webb, D. J., Bains, C., Barrett, S. J., Lai, R. Y., Laroche, J. P., Hosford, D., Maher-Edwards, G., and Weil, J. G. (2008) Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. J. Alzheimers Dis. 14, 301-311
18. Cano, S. J., Posner, H. B., Moline, M. L., Hurt, S. W., Swartz, J., Hsu, T., and Hobart, J.C. (2010) The ADAS-cog in Alzheimer'sdiseaseclinical trials: psychometric evaluation of the sum and its parts. J. Neurol. Neurosurg. Psychiatry 81, 1363-1368
19. Petersen, R. C. (2004) Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183-194
20. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A.M., Iwatsubo, T., Jack, C.R., Jr., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H. (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292
21. Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., Meguro, K., O'brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., Stern, Y., Visser, P. J., and Scheltens, P. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746
22. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
23. Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M., and Trojanowski, J. Q.; Alzheimer's Disease Neuroimaging Initiative. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403-413
24. Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G., Onyike, C. U., Hillis, A. E., Josephs, K. A., Boeve, B. F., Kertesz, A., Seeley, W.W., Rankin, K. P., Johnson, J. K., Gorno-Tempini, M. L., Rosen, H., Prioleau-Latham, C. E., Lee, A., Kipps, C. M., Lillo, P., Piguet, O., Rohrer, J. D., Rossor, M. N., Warren, J. D., Fox, N. C., Galasko, D., Salmon, D. P., Black, S. E., Mesulam, M., Weintraub, S., Dickerson, B. C., Diehl-Schmid, J., Pasquier, F., Deramecourt, V., Lebert, F., Pijnenburg, Y., Chow, T.W., Manes, F., Grafman, J., Cappa, S. F., Freedman, M., Grossman, M., and Miller, B. L. (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456-2477
25. Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J.M., Rohrer, J. D., Black, S., Boeve, B. F., Manes, F., Dronkers, N. F., Vandenberghe, R., Rascovsky, K., Patterson, K., Miller, B. L., Knopman, D. S., Hodges, J. R., Mesulam, M.M., and Grossman, M. (2011) Classification of primary progressive aphasia and its variants. Neurology 76, 1006-1014
26. Parks, K. M., Sugar, J. E., Haroutunian, V., Bierer, L., Perl, D., and Wallace, W. C. (1991) Reduced in vitro phosphorylation of synapsin I (site 1) in Alzheimer's disease postmortem tissues. Brain Res. Mol. Brain Res. 9, 125-134
27. Rosahl, T. W., Geppert, M., Spillane, D., Herz, J., Hammer, R. E., Malenka, R.C., and Südhof, T.C. (1993) Short-termsynaptic plasticity is altered in mice lacking synapsin I. Cell 75, 661-670
28. 2+-dependent formation of a dynamin-synaptophysin complex: potential role in synaptic vesicle endocytosis. J. Biol. Chem. 277, 9010-9015
29. Valtorta, F., Pennuto, M., Bonanomi, D., and Benfenati, F. (2004) Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis? Bio Essays 26, 445-453
30. Sudhof, T.C. (2004) The synaptic vesicle cycle. Annu. Rev. Neurosci. 27, 509-547
31. 2+-dependent interaction of the growth-associated protein GAP-43 with the synaptic core complex. Biochem. J. 325, 455-463
32. Bacaj, T., Wu, D., Burré, J., Malenka, R. C., Liu, X., and Südhof, T. C. (2015) Synaptotagmin-1 and -7 are redundantly essential for maintaining the capacity of the readily-releasable pool of synaptic vesicles. PLoS Biol. 13, e1002267
33. Jackman, S. L., Turecek, J., Belinsky, J. E., and Regehr, W. G. (2016) The calcium sensor synaptotagmin 7 is required for synaptic facilitation. Nature 529, 88-91
34. Kvartsberg, H., Duits, F.H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., Andreasson, U., Teunissen, C. E., Scheltens, P., Van der Flier, W. M., Zetterberg, H., Portelius, E., and Blennow, K. (2015) Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline inprodromal Alzheimer's disease. Alzheimers Dement. 11, 1180-1190
35. Kester, M. I., Teunissen, C. E., Crimmins, D. L., Herries, E. M., Ladenson, J. H., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., and Fagan, A. M. (2015) Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol. 72, 1275-1280
36. Regan, P., Whitcomb, D. J., and Cho, K. (2016) Physiological and pathophysiological implications of synaptic tau. [E-pub ahead of print] Neuroscientist doi: 10.1177/1073858416633439